13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002003147
Total reported value
$586.5M
$586.5M
17 檔
28.5%
The Q1 2026 SEC filing reveals that Davern Capital Partners, LP held a total portfolio value of $586.5M, covering 17 public equity positions.
In Q1 2026, Davern Capital Partners, LP displayed an active expansion posture, initiating 4 new positions and adding to 7 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PFE | Pfizer Inc | Stock-Healthcare | 12.28% | -12.28% | EXIT | |
| 2 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 9.50% | +0.35% | -14.54% | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 8.19% | +1.99% | — | |
| 4 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 7.97% | +2.83% | +62.24% | |
| 5 | NTRA | Natera Inc | Stock-Healthcare | 7.90% | -2.39% | +83.05% | |
| 6 | BNTX | Biontech Se-adr | Stock-Other | 7.44% | +4.53% | -17.82% | |
| 7 | ARGX | Argenx Se - Adr | Stock-Healthcare | 7.02% | -7.02% | EXIT | |
| 8 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.88% | -6.88% | EXIT | |
| 9 | RPRX | Royalty Pharma plc | Stock-Healthcare | 6.84% | +4.21% | -38.14% | |
| 10 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 6.64% | +5.02% | -15.06% | |
| 11 | LEGN | Legend Biotech Corp-adr | Stock-Other | 6.52% | -0.65% | +24.42% | |
| 12 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 3.32% | +0.63% | +112.28% | |
| 13 | ABVX | Abivax Sa-adr | Stock-Other | 2.39% | -2.39% | EXIT | |
| 14 | GENB | Generate Biomedicines Inc | Stock-Other | 2.03% | +0.34% | — | |
| 15 | PRCT | Procept Biorobotics CORP | Stock-Other | 1.79% | — | — | |
| 16 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.67% | +2.41% | — | |
| 17 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.62% | -1.62% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | +4% | +228.39% | Add |
| 2 | NTRA | Natera Inc | +2.1% | +83.05% | Add |
| 3 | IONS | Ionis Pharmaceuticals Inc | +1.9% | +62.24% | Add |
| 4 | MLYS | Mineralys Therapeutics Inc | +0.9% | +112.28% | Add |
| 5 | ABVX | Abivax Sa-adr | +0.3% | +61.08% | Add |
| 6 | ROIV | Roivant Sciences Ltd. | -0.6% | -15.06% | Trim |
| 7 | LEGN | Legend Biotech Corp-adr | -0.9% | +24.42% | Add |
| 8 | VRDN | Viridian Therapeutics Inc | -1% | +15.61% | Add |
| 9 | ARGX | Argenx Se - Adr | -2.7% | -1.79% | Trim |
| 10 | REGN | Regeneron Pharmaceuticals | -3.6% | -14.54% | Trim |
| 11 | RPRX | Royalty Pharma plc | -3.7% | -38.14% | Trim |
| 12 | BNTX | Biontech Se-adr | -4% | -17.82% | Trim |
| 13 | PFE | Pfizer Inc | -4.2% | -21.95% | Trim |
| 14 | INSM | Insmed Inc | — | NEW | New buy |
| 15 | GENB | Generate Biomedicines Inc | — | NEW | New buy |
| 16 | CGON | Cg Oncology Inc | — | EXIT | Sold out |
| 17 | PRCT | Procept Biorobotics CORP | — | NEW | New buy |
| 18 | GPCR | Structure Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Davern Capital Partners, LP reported a total U.S. public equity portfolio value of $586.5M across 17 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PFE, REGN, INSM) accounted for 28.5% of total reported equity market value during Q1 2026.
Top New Position Initiated
INSM
市值: $29.9M
Top Position Liquidated / Trimmed
CGON
前期市值: $6.7M
During Q1 2026, Davern Capital Partners, LP's top holdings by market value included PFE (12.3%)、REGN (9.5%)、INSM (8.2%). The largest single position, PFE, represented 12.3% of total portfolio value.
In Q1 2026, Davern Capital Partners, LP made 18 total portfolio adjustments, initiating 4 new buys, adding to 7 positions, trimming 6 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.